Cargando…

Alzheimer’s disease biomarkers in cerebrospinal fluid are stable with the Elecsys immunoassay to most pre-analytical influencing factors except freezing at -80 °C

BACKGROUND: Alzheimer´s disease is considered a neurodegenerative disease and is diagnosed by exclusion, while the detection of specific cerebrospinal fluid (CSF) biomarkers, namely amyloid-beta (Aβ) peptides Aβ1–42 (Aß42), phospho-tau (181P; P-tau), and total-tau (T-tau), has been shown to improve...

Descripción completa

Detalles Bibliográficos
Autores principales: Konen, Franz Felix, Maier, Hannah Benedictine, Neyazi, Alexandra, Bleich, Stefan, Neumann, Konstantin, Skripuletz, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10308606/
https://www.ncbi.nlm.nih.gov/pubmed/37381021
http://dx.doi.org/10.1186/s42466-023-00257-5
_version_ 1785066279771570176
author Konen, Franz Felix
Maier, Hannah Benedictine
Neyazi, Alexandra
Bleich, Stefan
Neumann, Konstantin
Skripuletz, Thomas
author_facet Konen, Franz Felix
Maier, Hannah Benedictine
Neyazi, Alexandra
Bleich, Stefan
Neumann, Konstantin
Skripuletz, Thomas
author_sort Konen, Franz Felix
collection PubMed
description BACKGROUND: Alzheimer´s disease is considered a neurodegenerative disease and is diagnosed by exclusion, while the detection of specific cerebrospinal fluid (CSF) biomarkers, namely amyloid-beta (Aβ) peptides Aβ1–42 (Aß42), phospho-tau (181P; P-tau), and total-tau (T-tau), has been shown to improve diagnostic accuracy. Recently, a new generation of sample tubes (Sarstedt false-bottom tubes) for the Elecsys CSF immunoassay for the determination of Alzheimer´s disease biomarkers in CSF was introduced, promising better measurability. However, the pre-analytic influencing factors have not yet been sufficiently investigated. METHODS: In 29 patients without Alzheimer’s disease diagnosis, CSF concentrations of Aß42, P-tau and T-tau were examined in native CSF and after different influencing interventions using the Elecsys immunoassay test method. The following influencing factors were analyzed: contamination with blood (10,000 and 20,000 erythrocytes/µl CSF), 14-day storage at 4 °C, blood contamination of CSF and 14-day storage at 4 °C, 14-day freezing at -80 °C in Sarstedt tubes or glass vials, 3-month intermediate storage at -80 °C in glass vials. RESULTS: Both storage at -80 °C for 14 days in Sarstedt false-bottom tubes and in glass vials and storage at -80 °C for 3 months in glass vials resulted in significant decreases in Aß42 (13% after 14 days in Sarstedt and 22% in glass vials, 42% after 3 months in glass vials), P-tau (9% after 14 days in Sarstedt and 13% in glass vials, 12% after 3 months in glass vials) and T-tau (12% after 14 days in Sarstedt and 19% in glass vials, 20% after 3 months in glass vials) concentrations in CSF. No significant differences were found for the other pre-analytical influencing factors. CONCLUSIONS: Measurements of the concentrations of Aß42, P-tau, and T-tau in CSF with use of the Elecsys immunoassay are robust to the pre-analytical influencing factors of blood contamination and duration of storage. Freezing at -80 °C results in significant reduction of biomarker concentrations regardless of the storage tube and must be considered in retrospective analysis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s42466-023-00257-5.
format Online
Article
Text
id pubmed-10308606
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-103086062023-06-30 Alzheimer’s disease biomarkers in cerebrospinal fluid are stable with the Elecsys immunoassay to most pre-analytical influencing factors except freezing at -80 °C Konen, Franz Felix Maier, Hannah Benedictine Neyazi, Alexandra Bleich, Stefan Neumann, Konstantin Skripuletz, Thomas Neurol Res Pract Research Article BACKGROUND: Alzheimer´s disease is considered a neurodegenerative disease and is diagnosed by exclusion, while the detection of specific cerebrospinal fluid (CSF) biomarkers, namely amyloid-beta (Aβ) peptides Aβ1–42 (Aß42), phospho-tau (181P; P-tau), and total-tau (T-tau), has been shown to improve diagnostic accuracy. Recently, a new generation of sample tubes (Sarstedt false-bottom tubes) for the Elecsys CSF immunoassay for the determination of Alzheimer´s disease biomarkers in CSF was introduced, promising better measurability. However, the pre-analytic influencing factors have not yet been sufficiently investigated. METHODS: In 29 patients without Alzheimer’s disease diagnosis, CSF concentrations of Aß42, P-tau and T-tau were examined in native CSF and after different influencing interventions using the Elecsys immunoassay test method. The following influencing factors were analyzed: contamination with blood (10,000 and 20,000 erythrocytes/µl CSF), 14-day storage at 4 °C, blood contamination of CSF and 14-day storage at 4 °C, 14-day freezing at -80 °C in Sarstedt tubes or glass vials, 3-month intermediate storage at -80 °C in glass vials. RESULTS: Both storage at -80 °C for 14 days in Sarstedt false-bottom tubes and in glass vials and storage at -80 °C for 3 months in glass vials resulted in significant decreases in Aß42 (13% after 14 days in Sarstedt and 22% in glass vials, 42% after 3 months in glass vials), P-tau (9% after 14 days in Sarstedt and 13% in glass vials, 12% after 3 months in glass vials) and T-tau (12% after 14 days in Sarstedt and 19% in glass vials, 20% after 3 months in glass vials) concentrations in CSF. No significant differences were found for the other pre-analytical influencing factors. CONCLUSIONS: Measurements of the concentrations of Aß42, P-tau, and T-tau in CSF with use of the Elecsys immunoassay are robust to the pre-analytical influencing factors of blood contamination and duration of storage. Freezing at -80 °C results in significant reduction of biomarker concentrations regardless of the storage tube and must be considered in retrospective analysis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s42466-023-00257-5. BioMed Central 2023-06-29 /pmc/articles/PMC10308606/ /pubmed/37381021 http://dx.doi.org/10.1186/s42466-023-00257-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Konen, Franz Felix
Maier, Hannah Benedictine
Neyazi, Alexandra
Bleich, Stefan
Neumann, Konstantin
Skripuletz, Thomas
Alzheimer’s disease biomarkers in cerebrospinal fluid are stable with the Elecsys immunoassay to most pre-analytical influencing factors except freezing at -80 °C
title Alzheimer’s disease biomarkers in cerebrospinal fluid are stable with the Elecsys immunoassay to most pre-analytical influencing factors except freezing at -80 °C
title_full Alzheimer’s disease biomarkers in cerebrospinal fluid are stable with the Elecsys immunoassay to most pre-analytical influencing factors except freezing at -80 °C
title_fullStr Alzheimer’s disease biomarkers in cerebrospinal fluid are stable with the Elecsys immunoassay to most pre-analytical influencing factors except freezing at -80 °C
title_full_unstemmed Alzheimer’s disease biomarkers in cerebrospinal fluid are stable with the Elecsys immunoassay to most pre-analytical influencing factors except freezing at -80 °C
title_short Alzheimer’s disease biomarkers in cerebrospinal fluid are stable with the Elecsys immunoassay to most pre-analytical influencing factors except freezing at -80 °C
title_sort alzheimer’s disease biomarkers in cerebrospinal fluid are stable with the elecsys immunoassay to most pre-analytical influencing factors except freezing at -80 °c
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10308606/
https://www.ncbi.nlm.nih.gov/pubmed/37381021
http://dx.doi.org/10.1186/s42466-023-00257-5
work_keys_str_mv AT konenfranzfelix alzheimersdiseasebiomarkersincerebrospinalfluidarestablewiththeelecsysimmunoassaytomostpreanalyticalinfluencingfactorsexceptfreezingat80c
AT maierhannahbenedictine alzheimersdiseasebiomarkersincerebrospinalfluidarestablewiththeelecsysimmunoassaytomostpreanalyticalinfluencingfactorsexceptfreezingat80c
AT neyazialexandra alzheimersdiseasebiomarkersincerebrospinalfluidarestablewiththeelecsysimmunoassaytomostpreanalyticalinfluencingfactorsexceptfreezingat80c
AT bleichstefan alzheimersdiseasebiomarkersincerebrospinalfluidarestablewiththeelecsysimmunoassaytomostpreanalyticalinfluencingfactorsexceptfreezingat80c
AT neumannkonstantin alzheimersdiseasebiomarkersincerebrospinalfluidarestablewiththeelecsysimmunoassaytomostpreanalyticalinfluencingfactorsexceptfreezingat80c
AT skripuletzthomas alzheimersdiseasebiomarkersincerebrospinalfluidarestablewiththeelecsysimmunoassaytomostpreanalyticalinfluencingfactorsexceptfreezingat80c